Targeting TRIM26: Unveiling an Oncogene and Identification of Plant Metabolites as a Potential Therapeutics for Breast Cancer

• Published in: Journal of cellular biochemistry Vol. 125; no. 10; pp. e30644 - n/a
• Main Authors: Makwana, Sweta H., Sharma, Tannavi, Mahapatra, Manas K., Kumari, Monika, Jain, Akshat, Shrivastava, Sandeep K., Mandal, Chandi C.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2024
• Subjects: Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer therapies; Cell cycle; Cell Line, Tumor; Cell migration; Cell Movement; Cell Proliferation; Coils; epithelial to mesenchymal transition; Female; Gene Expression Regulation, Neoplastic; Gene silencing; Genes; Humans; Malignancy; MCF-7 Cells; Metabolites; Metastases; molecular docking; Oncogenes; Proteins; siRNA; TCGA analysis; TRIM26; Tripartite Motif Proteins - genetics; Tripartite Motif Proteins - metabolism; Ubiquitin-Protein Ligases - genetics; Ubiquitin-Protein Ligases - metabolism; breast cancer; epithelial to mesenchymal transition; TRIM26; molecular docking; TCGA analysis
• ISSN: 0730-2312; 1097-4644; 1097-4644
• DOI: 10.1002/jcb.30644

ABSTRACT Breast cancer is the major cause of cancer‐related mortality and frequent malignancies among women worldwide. The TRIM (Tripartite Motif) protein family is a broad and diverse set of proteins that contain a conserved structural motif known as the tripartite motif, which comprises of three different domains, B‐box domain, Coiled‐coil domain and RBR (Ring‐finger, B‐box, and coiled‐coil) domain. TRIM proteins are involved in regulating cancer growth and metastasis. However, TRIM proteins are still unexplored in cancer cell regulation. In this study, by using a cancer database expression of all TRIM proteins was determined in breast cancer. Out of 77 TRIM genes, 16 genes were upregulated in breast cancer. Here, the upregulated TRIM26 gene's role is not yet explored in breast cancer. Indeed, TRIM26 is upregulated in 21 cancer types out of 33 cancer types. To investigate the role of TRIM26 in breast cancer, siRNA‐mediated gene silencing was carried out in MCF‐7 and MDA‐MB 231 breast cancer cells. Reduced expression of TRIM 26 decreased cancer cell proliferation, migration and invasion with simultaneous reduction of various proliferative, cell cycle and mesenchymal markers and upregulation of epithelial markers. Further, docking studies found potential novel plant metabolites. Thus, targeting TRIM26 may provide a novel therapeutic approach for breast cancer treatment.